A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer

Achieving tumor shrinkage may be a clinically relevant improvement in the treatment of metastatic colorectal cancer (mCRC). The present study attempted to evaluate early tumor shrinkage (ETS) and deepness of response over 6–8 courses of therapy, which were assessed previously in first-line trials of...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuhashi, Nobuhisa, Takahashi, Takao, Matsui, Satoshi, Tanahashi, Toshiyuki, Imai, Hisashi, Tanaka, Yoshihiro, Yamaguchi, Kazuya, Yoshida, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873832/
https://www.ncbi.nlm.nih.gov/pubmed/29568913
http://dx.doi.org/10.3892/ijo.2018.4322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873832/
https://www.ncbi.nlm.nih.gov/pubmed/29568913
http://dx.doi.org/10.3892/ijo.2018.4322

Ejemplares similares